CoChat

Substance use: a powerful predictor of relapse in schizophrenia

The DOI matches its Crossref record; 23 of the 26 references it cites were found in a registry or an index.

Abstract

This study examined substance use among a group of 37 schizophrenia patients participating in a year-long fluphenazine decanoate (FD; Prolixin) dosage reduction study (Inderbitzin et al. (1994) Am. J. Psychiatry 151, 1753-1759). Ten (50%) of the 20 FD dose-reduced patients, and 6 (35%) of the 17 control group patients were identified as substance users. The dose-reduced and control groups did not differ significantly in substance use. We examine here the 37 patients regrouped by substance users (n = 16) versus non-users (n = 21) to determine the effects of substance use. In addition to identifying substance users and types of substances used, we hypothesize that substance users differ demographically from non-users, have worse symptomatology, worse compliance, higher rates of relapse, and therefore, can confound studies. Clinical and demographic data were obtained. At least half of the substance users were using alcohol or cocaine. The substance use group had a significantly higher severity of illness score on the BPRS at study onset. We found no significant differences between the two groups on other rating scales. The non-use group lived more independently, and the substance use group was younger. The substance use group had nearly twice as many hospitalizations in the 2 years prior to the study, a greater rate of missed appointments in the year before and during the study, and 4 times as many relapses during the year of the study than the non-use group. The key finding was…

Overview

Integrity signals

Registry

Crossref · 10.1016/0920-9964(95)00068-2

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 249

Metadata

Authors
Swofford, C. D., Kasckow, J. W., Scheller-Gilkey, G., & Inderbitzin, L. B.
Affiliations
  • Grady Memorial Hospital (US)
  • Emory University (US)
Corresponding author
Swofford, Cheryl D.
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
1996-05
Volume
20
Issue
1-2
Pages
145-151
ISSN
0920-9964 (ISSN-L)
OpenAlex
W2014347408
Cited by
247
References
26
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 9 · 2017: 9 · 2016: 3 · 2015: 4 · 2014: 10 · 2013: 13 · 2012: 10
FWCI
4.39
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
substance use, schizophrenia
MeSH terms
Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluphenazine, Humans, Male, Middle Aged, Patient Compliance, Prognosis, Psychotropic Drugs, Recurrence, Schizophrenia, Schizophrenic Psychology, Illicit Drugs, Antipsychotic Agents, Comorbidity, Diagnosis, Dual (Psychiatry), Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Substance use: a powerful predictor of relapse in schizophrenia. https://app.cochat.ai/papers/10.1016/0920-9964(95)00068-2
The paper
Swofford, C. D., Kasckow, J. W., Scheller-Gilkey, G., & Inderbitzin, L. B. (1996). Substance use: a powerful predictor of relapse in schizophrenia. Schizophrenia Research. https://doi.org/10.1016/0920-9964(95)00068-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.